Bullish Case: Inferred: the +11.7% week off $1.24 shows buyers defending the $1.20 shelf; known: P/B 0.8 caps fundamental downside. The Helium return surface retains mass in high positive bins (historical span reaching ~+169%), so violent recoveries from washed-out levels have precedent. Uncertain catalyst: an early-November Q3 print with subscriber/EBITDA momentum could re-rate price to $1.70–2.20; confirmation requires three-day closes above $1.70, not one illiquid print.

Bearish Case: Known: -33% (90d), -77% YoY; every 2026 stabilization call failed as trend dominated. The return surface's sampled slice (-81% to -71.5%) brackets GAIA's realized multi-year drawdowns—catastrophic outcomes carry real historical mass. SPY's IV surface keeps ~35% vol on deep-OTM puts out 300+ days (inferred: persistent macro-hedging, risk-off vulnerability for illiquid microcaps). Uncertain: a Nasdaq minimum-bid deficiency if $1.00 breaks for 30 sessions, adding forced-selling pressure.

Potential Outcomes:

1. 40% Chop $1.20–1.70 into Dec (surface mode ≈0% short-horizon); falsify: 3-day close outside band.
2. 25% Break <$1.20 toward $0.90–1.20 on Q3 miss (~early Nov, cadence-inferred) or SPY risk-off; falsify: volume reclaim of $1.50.
3. 20% Rebound $1.70–2.20 on earnings beat; falsify: rejection at $1.70.
4. 10% Washout <$0.90: liquidity vacuum.
5. 5% Rerate >$2.50, verified catalyst. Oracle: listed IVs (200–500%, zero volume) are stale; treat the +11.7% week as noise until $1.70 holds.

September 30, 2026